John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, chairs a discussion with Wyndham Wilson, MD, PhD, of the National Cancer Institute, Bethesda, MD, on the highlights from the second day of the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting. They discuss a phase 1b/2 clinical trial that was designed to assess the safety and efficacy of ibrutinib and lenalidomide in combination with chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates